Detalhe da pesquisa
1.
Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.
J Clin Pharmacol
; 48(1): 85-95, 2008 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-17986525
2.
The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers.
Br J Clin Pharmacol
; 65(3): 338-46, 2008 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-17961192
3.
Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus.
Clin Pharmacokinet
; 46(7): 577-88, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-17596103
4.
The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers.
Clin Pharmacokinet
; 46(9): 787-802, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-17713976
5.
Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers.
J Clin Pharmacol
; 47(9): 1152-8, 2007 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-17656620
6.
Effect of food on the pharmacokinetics of a vildagliptin/metformin (50/1000 mg) fixed-dose combination tablet in healthy volunteers.
Curr Med Res Opin
; 24(6): 1703-9, 2008 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-18471347
7.
Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects.
Curr Med Res Opin
; 23(12): 2913-20, 2007 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-17931461
8.
Pharmacokinetics of enteric-coated mycophenolate sodium in stable pediatric renal transplant recipients.
Pediatr Transplant
; 9(6): 780-7, 2005 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-16269051